Long Term, Single-arm, Open-label Extension Study of Protocol AC-055-305 to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome

Trial Profile

Long Term, Single-arm, Open-label Extension Study of Protocol AC-055-305 to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Nov 2017

At a glance

  • Drugs Macitentan (Primary)
  • Indications Eisenmenger complex
  • Focus Adverse reactions
  • Acronyms MAESTRO-OL
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 05 Sep 2017 Planned End Date changed from 30 Aug 2018 to 30 Nov 2017.
    • 05 Sep 2017 Planned primary completion date changed from 31 Jul 2018 to 30 Nov 2017.
    • 03 Jul 2017 Planned End Date changed from 1 Sep 2020 to 30 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top